All three drugs (Flutamide, Docetaxel, and Ganoderma lucidum polysaccharide) and their combination significantly decreased the expression of the prostate cancer biomarker entitled KLK2 (P < 0.01). The gene discussed is KLK2; the disease is prostate cancer.